For example, here we reported that KDOAM-25 shows an inverse relationship between KDM5B expression and overall survival using data from three clinical multiple myeloma trials, thus suggesting a potential application for KDM5B inhibitors in myeloma therapy. Here, KDM5B is linked to AL amyloidosis.